Wang Shuai, Zheng Wei, Ji Alin, Zhang Dahong, Zhou Mi
Department of Urology, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou 310014, Zhejiang Province, People's Republic of China.
Cancer Manag Res. 2019 Nov 15;11:9701-9713. doi: 10.2147/CMAR.S225742. eCollection 2019.
Renal cancer is one of the most deadly urological malignancies. Currently, there is still a lack of effective treatment. Our purpose was to explore the mechanisms of miR-122-5p in renal cancer.
The expression levels of miR-122-5p and pyruvate kinase M2 (PKM2) in renal cancer cells were detected by RT-qPCR and Western blot analyses, respectively. Then, we measured the cell viability after knockdown of miR-122-5p and PKM2 using CCK-8 assay. Moreover, flow cytometry was used to investigate cell cycle and apoptosis of renal cancer cells. The cell migration of renal cancer cells transfected by miR-122-5p inhibitor and siPKM2 was then detected by wound healing assay. Furthermore, glucose consumption and lactate production were measured. Autophagy-related protein LCII/I was detected by Western blot.
MiR-122-5p was upregulated in renal cancer cells compared to HK2 cells, especially in 786-O cells. We found that silencing miR-122-5p promoted PKM2 expression in 786-O cells. After transfection of siPKM2 or miR-122-5p inhibitor, the cell viability of 786-O cells was significantly reduced. Furthermore, the G1 phase of 786-O cells was significantly blocked, and the S phase was significantly increased. In addition, knockdown of miR-122-5p or PKM2 promoted renal cancer cell apoptosis and inhibited cell migration. Glucose consumption of 786-O cells was significantly increased after transfection by siPKM2. Silencing miR-122-5p significantly promoted the expression levels of LCII/I.
Our findings revealed that overexpressed miR-122-5p promotes renal cancer cell viability, proliferation, migration, glycolysis and autophagy by negatively regulating PKM2, which provide a new insight for the development of renal cancer therapy.
肾癌是最致命的泌尿系统恶性肿瘤之一。目前,仍缺乏有效的治疗方法。我们的目的是探索miR-122-5p在肾癌中的作用机制。
分别通过RT-qPCR和蛋白质免疫印迹分析检测肾癌细胞中miR-122-5p和丙酮酸激酶M2(PKM2)的表达水平。然后,我们使用CCK-8法检测敲低miR-122-5p和PKM2后的细胞活力。此外,采用流式细胞术研究肾癌细胞的细胞周期和凋亡。通过划痕实验检测miR-122-5p抑制剂和siPKM2转染的肾癌细胞的细胞迁移情况。此外,还测量了葡萄糖消耗和乳酸生成。通过蛋白质免疫印迹检测自噬相关蛋白LCII/I。
与HK2细胞相比,肾癌细胞中miR-122-5p上调,尤其是在786-O细胞中。我们发现沉默miR-122-5p可促进786-O细胞中PKM2的表达。转染siPKM2或miR-122-5p抑制剂后,786-O细胞的细胞活力显著降低。此外,786-O细胞的G1期显著受阻,S期显著增加。此外,敲低miR-122-5p或PKM2可促进肾癌细胞凋亡并抑制细胞迁移。转染siPKM2后,786-O细胞的葡萄糖消耗显著增加。沉默miR-122-5p显著促进LCII/I的表达水平。
我们的研究结果表明,过表达的miR-122-5p通过负调控PKM2促进肾癌细胞的活力增殖、迁移、糖酵解和自噬,这为肾癌治疗的发展提供了新的见解。